美托洛尔对梗阻性肥厚型心肌病患者运动血流动力学的影响
这项随机双盲安慰剂对照交叉试验纳入28例NYHA≥II级的梗阻性肥厚型心肌病患者,比较美托洛尔150mg与安慰剂对静息和运动时侵入性血流动力学的影响。主要终点峰值运动与静息肺毛细血管楔压差(ΔPCWP)在两组间无差异(21±9 vs 23±9 mm Hg,P=0.12)。美托洛尔降低静息和峰值运动心率及左室流出道压差,增加每搏量。
要点
- 美托洛尔未改变运动引起的肺毛细血管楔压异常升高。
- 美托洛尔降低静息和峰值运动时左室流出道压差。
- 美托洛尔增加静息和峰值运动每搏量。
核心结论
- 在梗阻性肥厚型心肌病患者中,运动与肺毛细血管楔压异常升高相关,美托洛尔未影响该变化。
- 美托洛尔通过改变舒张末期容积、左室流出道压差和二尖瓣反流程度,增加静息和峰值运动每搏量。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,纳入28例梗阻性肥厚型心肌病且NYHA功能分级≥II级患者。
- 患者随机接受美托洛尔150 mg或安慰剂,连续2个2周治疗期,每期末行静息和运动右心导管及超声心动图检查。
- 主要终点为峰值运动与静息肺毛细血管楔压差值(ΔPCWP)。
主要发现
- 美托洛尔与安慰剂相比,ΔPCWP无治疗效应(21±9 mm Hg vs 23±9 mm Hg;P=0.12)。
- 静息时美托洛尔降低心率(P<0.0001)和左室流出道压差(P=0.01),增加左室舒张末期容积(P=0.02)和每搏量(+6.4;95%CI:0.02-17.7;P=0.049)。
- 峰值运动时美托洛尔降低心率(P<0.0001)、左室流出道压差(P=0.0005)和二尖瓣反流程度(P=0.004),增加每搏量(+9 mL;95%CI:2-15 mL;P=0.008)。
临床怎么用
- 对于梗阻性肥厚型心肌病患者,美托洛尔虽未改善运动肺毛细血管楔压,但可降低左室流出道压差并增加每搏量。
局限性
- 样本量较小(28例),可能限制结果的普遍性。
- 治疗周期较短(每期2周),长期效应未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between exercise hemodynamics, loading conditions, and medical treatment in patients with obstructive hypertrophic cardiomyopathy (HCM) is incompletely understood. OBJECTIVES: This study aimed to investigate the effect of metoprolol on invasive hemodynamic parameters at rest and during exercise in patients with obstructive HCM. METHODS: This randomized, double-blind, placebo-controlled crossover trial enrolled 28 patients with obstructive HCM and New York Heart Association functional class ≥II. Patients were randomized to initiate either metoprolol 150 mg or placebo for 2 consecutive 2-week periods. Right-heart catheterization and echocardiography were performed at rest and during exercise at the end of each treatment period. The primary outcome was the difference in pulmonary capillary wedge pressure (ΔPCWP) between peak exercise and rest. RESULTS: No treatment effect on ΔPCWP was observed between metoprolol and placebo treatment (21 ± 9 mm Hg vs 23 ± 9 mm Hg; P = 0.12). At rest, metoprolol lowered heart rate (P < 0.0001), left ventricular outflow tract (LVOT) gradient (P = 0.01), and increased left ventricular end-diastolic volume (P = 0.02) and stroke volume (SV) (+6.4; 95% CI: 0.02-17.7; P = 0.049). During peak exercise, metoprolol was associated with a lower heart rate (P < 0.0001), a lower LVOT gradient (P = 0.0005), lesser degree of mitral regurgitation (P = 0.004), and increased SV (+9 mL; 95% CI: 2-15 mL; P = 0.008). CONCLUSIONS: In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree of mitral regurgitation. (The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802).
引用
- Dybro AM, Rasmussen TB, Nielsen RR, et al. Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2022. PMID: 35450573. doi:10.1016/j.jacc.2022.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。